IEEE RE-Think Health Podcast
The IEEE Re-Think Health Podcast is an interview-style podcast where global healthcare stakeholders– technologists, researchers, clinicians, patient advocates, regulators, and more– re-think the approach to healthcare, from therapeutic discovery through bedside practice, utilizing new technologies and applications. The new frontiers of health tech have to be pragmatic, responsible and trusted to deliver optimal patient outcomes with security, privacy, and sustainable equitable access to quality care for all individuals. Welcome to the conversation!
Listen on:
IEEE SA RE-Think Health
IEEE SA RE-Think Health podcast shares insights and perspectives from the IEEE SA community, subject matter experts, and industry leaders that are working to raise the world's standards, drive market solutions, and much more, keeping you at the forefront of technological innovation for the benefit of humanity.
Episodes
Tuesday May 09, 2023
Tuesday May 09, 2023
Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare & Life Sciences (HLS) Practice Lead at the IEEE Standards Association (IEEE SA), interviews Walter De Brouwer, CEO & Founder of Doc.ai and Chair of the IEEE SA Technology and Data Harmonization for Enabling Decentralized Clinical Trials Industry Connections (IC) Program to discuss decentralizing clinical trials, addressing remote health challenges during COVID-19, and how to engage in the IC program.
Tuesday May 09, 2023
Tuesday May 09, 2023
The newly released IEEE 2791 open source standard on bioinformatic analyses from high throughput screening (HTS) faciliates an expedited bioinformatics communications exchange protocol amongst critical stakeholders in the clinical research phase.
Maria Palombini, Director of Emerging Communities & Opportunities Development and Healthcare and Life Sciences (HLS) Practice Lead at IEEE Standards Association (IEEE SA), interviews Raja Mazumder and Jonathon Keeney to shine a spotlight on the many different use cases from submissions for FDA regulatory review, to potential COVID-19 antibody research and other vaccine and infectious disease development applications.